Vericiguat pharmacokinetics as well as exposure–response relationships for pharmacodynamic markers of safety (hemodynamics) and efficacy (N-terminal pro-B-type natriuretic peptide plasma concentration [NT-proBNP]) were investigated in patients with heart failure and left ventricular ejection fraction < 45%

Vericiguat combined with guideline-directed medical therapy (standard of care) had no long-term effects on blood pressure in patients with heart failure and left ventricular ejection fraction < 45%

Reductions in [NT-proBNP] with vericiguat treatment combined with standard of care were dependent on vericiguat exposure as well as baseline [NT-proBNP] and led to a stronger NT-proBNP decrease with vericiguat than with standard of care alone